2015, Número 5
<< Anterior Siguiente >>
Ann Hepatol 2015; 14 (5)
Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3
Frider B, Castillo A, Gordo-Gilart R, Bruno A, Amante M, Alvarez L, Mathet V
Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 745-751
Archivo PDF: 222.66 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 2012; 36: 26-35.
Daleke D. Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003; 44: 233-42.
Chan J, and VandeBerg J. Hepatobiliary transport in health and disease. Clin Lipidol 2012; 7: 189-202.
Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30:134-46.
Sundaram SS, Sokol RJ. The Multiple Facets of ABCB4 (MDR3) Deficiency. Curr Treat Options Gastroenterol 2007; 10: 495-503.
Stapelbroek J, van Erpecum K, Klomp L, Houwen R. Liver disease associated with canalicular transport defects: Current and future therapies. J Hepatol 2010; 52: 258-71.
Jacquemin E, De Vree JM, Cresteil D, Sokal E, Sturm E, Dumont M, Scheffer G, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58.
Colombo C, Vajro P, Degiorgio D, Coviello D, Costantino L, Tornillo L, Motta V, et al. Clinical features and genotype- phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 2011; 52: 73-83.
Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2006; 453: 601-10.
Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci 2009; 14: 4242-56.
Gordo-Gilart R, Andueza S, Hierro L, Martínez-Fernández P, D’Agostino D, Jara P, Alvarez L. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity. Gut 2015; 64: 147-55
Alvarez L, Jara P, Sanchez-Sabaté E, Hierro L, Larrauri J, Díaz MC, Camarena C, et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 2004; 20: 2451-60.
Martínez-Fernández P, Hierro L, Jara P, Alvarez L. Knockdown of ATP8B1 expression leads to specific down-regulation of the bile acid sensor FXR in HepG2 cells. Effect of the FXR agonist GW4064. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1119-G1129.
Gautherot J, Delautier D, Maubert MA, Aït-Slimane T, Bolbach G, Delaunay JL, Durand-Schneider AM, et al. Phosphorylation of ABCB4 impacts its function: insights from disease-causing mutations. Hepatology 2014; 60: 610-21.
Poupon R. Ursodeoxycholic acid and bile- acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36: 3-12.
Friedman SL, Bansal MB. Reversal of hepatic fibrosis -fact or fantasy? Hepatology 2006; 43: 82-8.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
Texto completo
Cómo citar este artículo